Highlights Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
25.07 ^USD	+2.49%		+3.72%	-15.07%

Apr. 17	Stifel Initiates Mirum Pharmaceuticals With Buy Rating, $48 Price Target	MT
Apr. 02	Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mirum Pharmaceuticals, Inc. receives Positive Reimbursement Recommendation for Livmarli (Maralixibat Oral Solution) by Canada?S Cadth for Patients with Cholestatic Pruritus in Alagille Syndrome	Apr. 02	CI
Mirum Pharmaceuticals Gets Additional FDA Approval for Livmarli	Mar. 13	DJ
US FDA approves expanded use of Mirum's liver disease drug	Mar. 13	RE
Mirum Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approve LIVMARLI (Maralixibat) Oral Solution for the Treatment of Cholestatic Pruritus in Patients Five Years of Age and Older with Progressive Familial Intrahepatic Cholestasis	Mar. 13	CI
Mirum Pharmaceuticals, Inc. Provides Sales Guidance for the Year 2024	Feb. 28	CI
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q4 Revenue $69.6M, vs. Street Est of $67.9M	Feb. 28	MT
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Mirum Pharmaceuticals, Inc. Provides Earnings Guidance for Fourth Quarter 2023 and Full Year 2023	Jan. 08	CI
Mirum Pharmaceuticals, Inc. Announces Data from EMBARK Phase 2b Study for Biliary Atresia	Dec. 18	CI
Mirum Pharmaceuticals, Inc. Presents New Data at the Liver Meeting	Nov. 13	CI
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Posts Q3 Revenue $47.7M, vs. Street Est of $38.6M	Nov. 02	MT
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Mirum Pharmaceuticals Says US FDA Extends Supplemental NDA Review for Livmarli to March 13; Shares Fall After Hours	23-10-17	MT
Mirum Pharmaceuticals, Inc. Announces New PDUFA Date for LIVMARLI for the Treatment of Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis	23-10-17	CI
Mirum Pharmaceuticals, Inc. Presents LIVMARLI Clinical Data and Real-World Evidence at NASPGHAN	23-10-07	CI
Mirum Pharmaceuticals, Inc. Announces Positive Phase 3 Restore Study Results Evaluating Chenodal in Patients with Cerebrotendinous Xanthomatosis	23-10-02	CI
Travere Therapeutics, Mirum Pharmaceuticals Say Sale of Travere's Bile Acid Product Portfolio to Mirum Completed	23-09-05	MT
Mirum Pharmaceuticals, Inc. completed the acquisition of Bile Acid Product Portfolio from Travere Therapeutics, Inc..	23-08-30	CI
Earnings Flash (MIRM) MIRUM PHARMACEUTICALS Reports Q2 Revenue $37.5M, vs. Street Est of $30.4M	23-08-03	MT
Mirum Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mirum Pharmaceuticals, Inc.

Equities

MIRM

US6047491013

Highlights

Filters